» Articles » PMID: 37376177

Evaluating the Acceptability, Swallowability, and Palatability of Film-Coated Mini-Tablet Formulation in Young Children: Results from an Open-Label, Single-Dose, Cross-Over Study

Abstract

Mini-tablets are advantageous over liquid formulations in overcoming challenges related to stability, taste, and dosage. This open-label, single-dose, cross-over study investigated the acceptability and safety of drug-free, film-coated mini-tablets in children aged 1 month-6 years (stratified: 4-6 years, 2-<4 years, 1-<2 years, 6-<12 months, and 1-<6 months), and their preference for swallowing either a high quantity of 2.0 mm or a low quantity of 2.5 mm diameter mini-tablets. The primary endpoint was acceptability derived from swallowability. The secondary endpoints were investigator-observed palatability, acceptability as a composite endpoint derived from both swallowability and palatability, and safety. Of 320 children randomized, 319 completed the study. Across all tablet sizes, quantities and age groups, acceptability rates based on swallowability were high (at least 87%). Palatability was rated as "pleasant/neutral" in 96.6% of children. The acceptability rates as per the composite endpoint were at least 77% and 86% for the 2.0 mm and 2.5 mm film-coated mini-tablets, respectively. No adverse events or deaths were reported. Recruitment in the 1-<6-months group was stopped early due to coughing-evaluated as "choked on" in three children. Both 2.0 mm and 2.5 mm film-coated mini-tablets are suitable formulations for young children.

Citing Articles

Challenges prescribing and dispensing oral antibiotics with poor palatability for paediatric patients: A qualitative interview study with GPs and pharmacists.

Elgammal A, Ryan J, Bradley C, Crean A, Bermingham M Explor Res Clin Soc Pharm. 2024; 17:100546.

PMID: 39691775 PMC: 11647503. DOI: 10.1016/j.rcsop.2024.100546.


Application of Hydrophilic Polymers to the Preparation of Prolonged-Release Minitablets with Bromhexine Hydrochloride and Bisoprolol Fumarate.

Grzejdziak A, Brniak W, Lengier O, Zarek J, Hliabovich D, Mendyk A Pharmaceutics. 2024; 16(9).

PMID: 39339190 PMC: 11434728. DOI: 10.3390/pharmaceutics16091153.


Questionnaire Study to Investigate the Preferences of Children, Parents, and Healthcare Professionals for Different Formulations of Oral Medicinal Products.

Wargenau M, Baase F, Eckardt K, Spitzhorn L, Reidemeister S, Klingmann I Pharmaceutics. 2024; 16(4).

PMID: 38675176 PMC: 11054268. DOI: 10.3390/pharmaceutics16040515.

References
1.
Schubart A, Anderson K, Mainolfi N, Sellner H, Ehara T, Adams C . Small-molecule factor B inhibitor for the treatment of complement-mediated diseases. Proc Natl Acad Sci U S A. 2019; 116(16):7926-7931. PMC: 6475383. DOI: 10.1073/pnas.1820892116. View

2.
Baliga S, Muglikar S, Kale R . Salivary pH: A diagnostic biomarker. J Indian Soc Periodontol. 2013; 17(4):461-5. PMC: 3800408. DOI: 10.4103/0972-124X.118317. View

3.
Schirm E, Tobi H, De Vries T, Choonara I, de Jong-van den Berg L . Lack of appropriate formulations of medicines for children in the community. Acta Paediatr. 2004; 92(12):1486-9. DOI: 10.1080/08035250310006728. View

4.
Schouten H, Kester A . A simple analysis of a simple crossover trial with a dichotomous outcome measure. Stat Med. 2009; 29(2):193-8. DOI: 10.1002/sim.3771. View

5.
Patel A, Jacobsen L, Jhaveri R, Bradford K . Effectiveness of pediatric pill swallowing interventions: a systematic review. Pediatrics. 2015; 135(5):883-9. DOI: 10.1542/peds.2014-2114. View